SCHEMBL6032026

SCHEMBL6032026

CC(C)(CC(=O)c1ccc(-c2ccc(NC=O)cc2)cc1)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.39
MAPT P10636 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
DGAT1 O75907 2/20 0.39
ALDH1A1 P00352 4/20 0.38
HAO1 Q9UJM8 4/20 0.37
HPGD P15428 1/20 0.37
ERCC5 P28715 1/20 0.37
FEN1 P39748 1/20 0.37
KDM4E B2RXH2 2/20 0.36
USP2 O75604 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
MEN1 O00255 1/20 0.36
CYP3A4 P08684 1/20 0.36
KMT2A Q03164 1/20 0.36
PTPN1 P18031 1/20 0.36
GSK3B P49841 1/20 0.36
KDM5A P29375 1/20 0.36
RAB9A P51151 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1748176 0.86 GAA (0.40) SMN1; SMN2MAPTL3MBTL1DGAT1ALDH1A1
SCHEMBL1748034 0.76 SMN1; SMN2 (0.44) SMN1; SMN2MAPTL3MBTL1ALDH1A1HAO1
SCHEMBL13752563 0.76 NPC1 (0.54) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL4428955 0.76 ALDH1A1 (0.50) SMN1; SMN2MAPTALDH1A1KDM4EMEN1
SCHEMBL5005972 0.75 TAAR1 (0.37) SMN1; SMN2MAPTALDH1A1KDM4EHDAC1
SCHEMBL5067991 0.75 RAB9A (0.50) SMN1; SMN2MAPTALDH1A1USP2MEN1
SCHEMBL13752572 0.74 RAB9A (0.58) SMN1; SMN2MAPTALDH1A1HPGDHDAC1
SCHEMBL17570995 0.74 MAPT (0.48) SMN1; SMN2MAPTL3MBTL1ALDH1A1HPGD
SCHEMBL4226915 0.73 RAB9A (0.50) SMN1; SMN2MAPTDGAT1ALDH1A1KDM4E
SCHEMBL13752741 0.72 RAB9A (0.54) SMN1; SMN2ALDH1A1MEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1633722-A2 PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY Bayer Pharmaceuticals Corporation (US) 2006-03-15 EP disclosed
WO-2004100881-A2 PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY BAYER PHARMACEUTICALS CORPORATION (US) 2004-11-25 WO disclosed